Sorafenib-induced premalignant and malignant skin lesions

Diagnosis and Follow-Up of Keratoacanthoma-Like Lesions: Clinical-Histologic Study of 43 Cases

(2015) Renata Ferreira Magalhães et al.   JOURNAL OF CUTANEOUS MEDICINE AND SURGERY

Regional Squamous Cell Carcinomas Following Systemic Sorafenib Therapy and Isolated Limb Infusion for Regionally Advanced Metastatic Melanoma of the Limb

(2010) Amanda K. Raymond et al.   ARCHIVES OF DERMATOLOGY

Compensatory activation of Akt in response to mTOR and Raf inhibitors – A rationale for dual-targeted therapy approaches in neuroendocrine tumor disease

(2010) Kathrin Zitzmann et al.   CANCER LETTERS

Cutaneous Squamous Cell Carcinoma and Inflammation of Actinic Keratoses Associated with Sorafenib

(2009) Zita Dubauskas et al.   Clinical Genitourinary Cancer

Eruptive Keratoacanthoma-Type Squamous Cell Carcinomas in Patients Taking Sorafenib for the Treatment of Solid Tumors

(2009) KATHLEEN J. SMITH et al.   DERMATOLOGIC SURGERY

Keratoacanthomas and Squamous Cell Carcinomas in Patients Receiving Sorafenib

(2009) Jean Philippe Arnault et al.   JOURNAL OF CLINICAL ONCOLOGY

The histologic spectrum of epithelial neoplasms induced by sorafenib

(2009) Eun Ji Kwon et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Array of cutaneous adverse effects associated with sorafenib

(2009) Heidi H. Kong et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Keratoacanthoma: hyperplasia, benign neoplasm, or a type of squamous cell carcinoma?

(2009) Joshua C. Mandrell et al.   SEMINARS IN DIAGNOSTIC PATHOLOGY

Multiple Squamous Cell Carcinomas of the Skin After Therapy With Sorafenib Combined With Tipifarnib

(2008) David S. Hong et al.   ARCHIVES OF DERMATOLOGY

Prospective Study of the Cutaneous Adverse Effects of Sorafenib, a Novel Multikinase Inhibitor

(2008) Julien Autier et al.   ARCHIVES OF DERMATOLOGY

Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses

(2008) M. M. Hipp et al.   BLOOD